Vaxcyte Inc
Research Vaxcyte Inc (PCVX) on Bullrun: market cap USD 8.84B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPCVX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 8.84B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 284.30M
- Free cash flow-USD 237.05M
Valuation Snapshot
latest market cap is USD 8.84B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 766.63K | -USD 669.29M | n/a | -5.63 | USD 173.96M | USD 117.48M | USD 2.69B |
| FY2024 | USD 0 | -USD 463.93K | -USD 475.05M | n/a | -3.8 | USD 387.88M | USD 71.11M | USD 3.31B |
| FY2023 | n/a | -USD 402.27K | -USD 312.85M | n/a | -4.14 | USD 397.45M | USD 29.22M | USD 1.24B |
| FY2022 | n/a | -USD 223.49K | -USD 176.44M | n/a | -3.44 | USD 834.66M | USD 21.20M | USD 953.61M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 8.84B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 6.05B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 10.22B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 5.98B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 3.79B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.26B | n/a | n/a | n/a |
About Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Vaxcyte Inc's market cap?
Vaxcyte Inc's market capitalization is USD 8.84B.
What does Vaxcyte Inc do?
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.